Exosomes from Bone Marrow Microenvironment-Derived Mesenchymal Stem Cells Affect CML Cells Growth and Promote Drug Resistance to Tyrosine Kinase Inhibitors

Table 1

The characteristics of the 16 patients with CML.

Patient number	Disease status	Gender	Age	WBC count (×109/L)	Karyotype	Anti-CML therapy
1	Chronic phase	M	60	138.5	t(9;22)(q34;q11)	None
2	Chronic phase	M	54	75.6	Complex	None
3	Accelerated phase	F	49	105.2	t(9;22)(q34;q11)	None
4	Chronic phase	F	51	46.3	t(9;22)(q34;q11)	None
5	Chronic phase	M	53	237.9	t(9;22)(q34;q11)	None
6	Accelerated phase	F	64	392.3	t(9;22)(q34;q11)	None
7	Accelerated phase	F	47	153.4	t(9;22)(q34;q11)	None
8	Blastic crisis	F	55	242.7	t(9;22)(q34;q11)	None
9	Blastic crisis	M	58	175.8	Complex	None
10	Chronic phase	M	39	409.1	t(9;22)(q34;q11)	None
11	Chronic phase	M	47	364.5	t(9;22)(q34;q11)	None
12	Chronic phase	F	62	283.4	t(9;22)(q34;q11)	None
13	Accelerated phase	M	60	196.7	t(9;22)(q34;q11)	None
14	Accelerated phase	F	44	83.5	t(9;22)(q34;q11)	None
15	Chronic phase	M	45	252.4	Complex	None
16	Chronic phase	M	47	375.9	t(9;22)(q34;q11)	None